转移性-话题@MedSci

#转移性#

975篇内容 | 2876人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, objectType=article, longId=739183, objectId=460ce39183f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460ce39183f7, replyNumber=0, likeNumber=144, createdTime=2022-09-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460ce39183f7, moduleTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=460ce39183f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, objectType=article, longId=739076, objectId=83fde390764d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83fde390764d, replyNumber=0, likeNumber=131, createdTime=2022-09-13, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83fde390764d, moduleTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83fde390764d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387033, encodeId=7dae138e033e8, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, objectType=article, longId=739074, objectId=6781e3907456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781e3907456, replyNumber=0, likeNumber=112, createdTime=2022-09-13, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781e3907456, moduleTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781e3907456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387032, encodeId=bbcd138e0324f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：叶定伟教授团队发现瑞维鲁胺治疗转移性激素敏感性前列腺癌疗效显著！（CHART研究）, objectType=article, longId=738964, objectId=ad9ce38964d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad9ce38964d4, replyNumber=0, likeNumber=128, createdTime=2022-09-12, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad9ce38964d4, moduleTitle=Lancet Oncol：叶定伟教授团队发现瑞维鲁胺治疗转移性激素敏感性前列腺癌疗效显著！（CHART研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad9ce38964d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387027, encodeId=d8bf138e02792, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：立体定向放疗和原位病毒基因疗法可增强免疫检查点阻滞对转移性三阴乳腺癌的疗效, objectType=article, longId=738744, objectId=e4d2e3874441, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4d2e3874441, replyNumber=0, likeNumber=139, createdTime=2022-09-11, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4d2e3874441, moduleTitle=Clin Cancer Res：立体定向放疗和原位病毒基因疗法可增强免疫检查点阻滞对转移性三阴乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4d2e3874441)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387028, encodeId=c52e138e028f4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后, objectType=article, longId=738674, objectId=c94ce38674b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c94ce38674b5, replyNumber=0, likeNumber=111, createdTime=2022-09-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c94ce38674b5, moduleTitle=Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c94ce38674b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387029, encodeId=45c4138e029f0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：艾瑞恩 vs 比卡鲁胺联合ADT治疗转移性激素阳性前列腺癌, objectType=article, longId=738668, objectId=be84e3866836, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be84e3866836, replyNumber=0, likeNumber=128, createdTime=2022-09-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be84e3866836, moduleTitle=Lancet Oncol：艾瑞恩 vs 比卡鲁胺联合ADT治疗转移性激素阳性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be84e3866836)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387030, encodeId=8eef138e030b3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JAMA Oncol：卡巴他赛在转移性/局部晚期去分化脂肪肉瘤中的活性, objectType=article, longId=738663, objectId=5cfee38663b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cfee38663b9, replyNumber=0, likeNumber=112, createdTime=2022-09-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cfee38663b9, moduleTitle=JAMA Oncol：卡巴他赛在转移性/局部晚期去分化脂肪肉瘤中的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cfee38663b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387031, encodeId=5b0c138e0317b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌, objectType=article, longId=738547, objectId=dd49e385472d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd49e385472d, replyNumber=0, likeNumber=116, createdTime=2022-09-09, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd49e385472d, moduleTitle=JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd49e385472d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387025, encodeId=836f138e0254f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, objectType=article, longId=737158, objectId=579ee371587c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579ee371587c, replyNumber=0, likeNumber=125, createdTime=2022-08-29, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579ee371587c, moduleTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=579ee371587c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387022, encodeId=10df138e022fb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：化疗后采用鲁卡帕尼维持治疗DNA修复缺陷阳性转移性尿路上皮癌, objectType=article, longId=736046, objectId=9162e3604691, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9162e3604691, replyNumber=0, likeNumber=113, createdTime=2022-08-18, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9162e3604691, moduleTitle=J Clin Oncol：化疗后采用鲁卡帕尼维持治疗DNA修复缺陷阳性转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9162e3604691)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387021, encodeId=f011138e02135, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Radiology：CT+CA19-9的强强联手：非转移性胰腺癌的治疗反应评估, objectType=article, longId=735694, objectId=74d3e3569400, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d3e3569400, replyNumber=0, likeNumber=116, createdTime=2022-08-13, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d3e3569400, moduleTitle=Radiology：CT+CA19-9的强强联手：非转移性胰腺癌的治疗反应评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74d3e3569400)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387020, encodeId=5b89138e020d7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：杜瓦鲁单抗联合曲美木单抗治疗晚期转移性肉瘤, objectType=article, longId=735665, objectId=e7a9e356655a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7a9e356655a, replyNumber=0, likeNumber=125, createdTime=2022-08-13, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7a9e356655a, moduleTitle=Lancet Oncol：杜瓦鲁单抗联合曲美木单抗治疗晚期转移性肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7a9e356655a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387019, encodeId=786d138e019db, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：一线化疗加用大剂量维C是否可改善转移性结直肠癌患者预后, objectType=article, longId=735294, objectId=f0bae3529407, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0bae3529407, replyNumber=0, likeNumber=114, createdTime=2022-08-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0bae3529407, moduleTitle=Clin Cancer Res：一线化疗加用大剂量维C是否可改善转移性结直肠癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0bae3529407)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387017, encodeId=5a80138e01740, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=易被误诊为转移性肺癌的多原发肺癌应该如何治疗？手术切除是治疗的首选！, objectType=article, longId=734751, objectId=6465e3475102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6465e3475102, replyNumber=0, likeNumber=120, createdTime=2022-08-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6465e3475102, moduleTitle=易被误诊为转移性肺癌的多原发肺癌应该如何治疗？手术切除是治疗的首选！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6465e3475102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387018, encodeId=b679138e018e6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=肺泡微石症、转移性肺钙化丨影像表现, objectType=article, longId=734746, objectId=b61de34746a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61de34746a2, replyNumber=0, likeNumber=92, createdTime=2022-08-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61de34746a2, moduleTitle=肺泡微石症、转移性肺钙化丨影像表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b61de34746a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387016, encodeId=5fd0138e01685, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：口服紫杉醇+Encequidar治疗转移性乳腺癌优胜静脉紫杉醇, objectType=article, longId=734111, objectId=cbaae3411181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbaae3411181, replyNumber=0, likeNumber=125, createdTime=2022-08-03, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbaae3411181, moduleTitle=J Clin Oncol：口服紫杉醇+Encequidar治疗转移性乳腺癌优胜静脉紫杉醇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbaae3411181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387015, encodeId=2c15138e01525, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=多中心真实世界研究：基于血浆ctDNA突变的转移性乳腺癌亚型临床分析, objectType=article, longId=733995, objectId=d8c5e3399568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8c5e3399568, replyNumber=0, likeNumber=105, createdTime=2022-08-01, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8c5e3399568, moduleTitle=多中心真实世界研究：基于血浆ctDNA突变的转移性乳腺癌亚型临床分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8c5e3399568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387013, encodeId=bff3138e01396, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, objectType=article, longId=733030, objectId=73fbe3303097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73fbe3303097, replyNumber=0, likeNumber=110, createdTime=2022-07-24, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73fbe3303097, moduleTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73fbe3303097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387014, encodeId=848e138e0146a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=European Radiology：深度学习分割算法在转移性肾癌患者中对骨骼肌指数的全自动量化, objectType=article, longId=732911, objectId=0848e3291171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0848e3291171, replyNumber=0, likeNumber=123, createdTime=2022-07-22, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0848e3291171, moduleTitle=European Radiology：深度学习分割算法在转移性肾癌患者中对骨骼肌指数的全自动量化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0848e3291171)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤

2022-09-15

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）

2022-09-13

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）

2022-09-13

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：叶定伟教授团队发现瑞维鲁胺治疗转移性激素敏感性前列腺癌疗效显著！（CHART研究）

2022-09-12

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：立体定向放疗和原位病毒基因疗法可增强免疫检查点阻滞对转移性三阴乳腺癌的疗效

2022-09-11

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后

2022-09-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：艾瑞恩 vs 比卡鲁胺联合ADT治疗转移性激素阳性前列腺癌

2022-09-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JAMA Oncol：卡巴他赛在转移性/局部晚期去分化脂肪肉瘤中的活性

2022-09-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌

2022-09-09

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！

2022-08-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：化疗后采用鲁卡帕尼维持治疗DNA修复缺陷阳性转移性尿路上皮癌

2022-08-18

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Radiology：CT+CA19-9的强强联手：非转移性胰腺癌的治疗反应评估

2022-08-13